A citation-based method for searching scientific literature

Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya, Lars Hansen, Fredrik Thorén, Anna Maria Langkilde. Diabetes Care 2018
Times Cited: 120



Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou, Bruce A Perkins. Diabetes Care 2018
Times Cited: 119




List of shared articles



Times cited

Acute Metabolic Emergencies in Diabetes: DKA, HHS and EDKA.
Muhammad Muneer, Ijaz Akbar. Adv Exp Med Biol 2021
2

Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
Bruce W Bode, Eda Cengiz, R Paul Wadwa, Phillip Banks, Thomas Danne, Jake A Kushner, Darren K McGuire, Anne L Peters, Paul Strumph, Sangeeta Sawhney. Diabetes Technol Ther 2021
2


Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Moshe Phillip, Chantal Mathieu, Marcus Lind, Eiichi Araki, Paolo di Bartolo, Richard Bergenstal, Simon Heller, Lars Hansen, Markus Florian Scheerer, Fredrik Thoren,[...]. Diabetes Obes Metab 2021
8


Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hailan Zou, Lili Liu, Jia Guo, Hongjuan Wang, Siyun Liu, Yixuan Xing, Chao Deng, Yang Xiao, Zhiguang Zhou. J Diabetes Investig 2021
2


Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.
Biff F Palmer, Deborah J Clegg. Clin J Am Soc Nephrol 2021
2

Current and future therapies for type 1 diabetes.
Bernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, Matthias von Herrath. Diabetologia 2021
8

Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.
Rhea Teng, Martin Kurian, Kelly L Close, John B Buse, Anne L Peters, Charles M Alexander. Diabetes Spectr 2021
1


A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.
Curtis K Johnston, Rena J Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M Riggs, Karl-Heinz Liesenfeld. Pharmaceutics 2021
0

Using adjuvant pharmacotherapy in the treatment of type 1 diabetes.
Åke Sjöholm. Expert Opin Pharmacother 2021
0

Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges.
Nuria Vilarrasa, Patricia San Jose, Miguel Ángel Rubio, Albert Lecube. Diabetes Metab Syndr Obes 2021
1

Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes.
Hongyan Liu, Vikas S Sridhar, Daniel Montemayor, Leif Erik Lovblom, Yuliya Lytvyn, Hongping Ye, Jiwan Kim, Mir Tariq Ali, Daniel Scarr, Patrick R Lawler,[...]. Diabetes Obes Metab 2021
0

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
David Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal. Diabetes Obes Metab 2021
0

Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Lian A van Meijel, Cees J Tack, Bastiaan E de Galan. Diabetes Obes Metab 2021
0


Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Thomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, Frederik F Kreiner, Lars Bardtrum, Matthias von Herrath, Chantal Mathieu, Sten Madsbad. Diabetes Obes Metab 2021
0

Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.
Melissa-Rosina Pasqua, Michael A Tsoukas, Ahmad Haidar. J Diabetes Sci Technol 2021
0

Multicenter, Open-Label, 2-Arm, Pilot Trial for Safe Reduction of Basal Insulin Dose Combined with SGLT2 Inhibitor in Type 1 Diabetes Mellitus: Study Protocol for a RISING-STAR Trial.
Masahide Hamaguchi, Yoshitaka Hashimoto, Toru Tanaka, Goji Hasegawa, Michiyo Ishii, Hiroshi Okada, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Emi Ushigome, Masahiro Yamazaki,[...]. Clin Med Insights Endocrinol Diabetes 2021
0

Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Bryony E Langford, Marc Evans, Tao Haskins-Coulter, Molly O'Connor, Harriet E O Cant, Lucy A Eddowes, Christopher Edmonds, Amarjeet Tank. Diabetes Obes Metab 2020
6

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Christian Hampp, Richard S Swain, Casie Horgan, Elizabeth Dee, Yandong Qiang, Sarah K Dutcher, Andrew Petrone, Rong Chen Tilney, Judith C Maro, Catherine A Panozzo. Diabetes Care 2020
17

Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Ane Bayona Cebada, Lía Nattero-Chávez, Sara Alonso Díaz, Héctor F Escobar-Morreale, Manuel Luque-Ramírez. Diabetes Technol Ther 2020
1



Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge.
C David Mazer, Amel Arnaout, Kim A Connelly, Jeremy D Gilbert, Stephen A Glazer, Subodh Verma, Ronald M Goldenberg. Curr Opin Cardiol 2020
1

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
15

Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Jennifer R Snaith, Deborah J Holmes-Walker, Jerry R Greenfield. Trends Endocrinol Metab 2020
9

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
14

Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Bruce A Perkins, Nima Soleymanlou, Julio Rosenstock, Jay S Skyler, Lori M Laffel, Karl-Heinz Liesenfeld, Dietmar Neubacher, Matthew M Riggs, Curtis K Johnston, Rena J Eudy-Byrne,[...]. Diabetes Obes Metab 2020
3

Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease.
Tina Schumann, Jörg König, Christine Henke, Diana M Willmes, Stefan R Bornstein, Jens Jordan, Martin F Fromm, Andreas L Birkenfeld. Pharmacol Rev 2020
28

Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone.
Kathryn M Thrailkill, R Clay Bunn, Sasidhar Uppuganti, Philip Ray, Kate Garrett, Iuliana Popescu, Jacquelyn S Pennings, John L Fowlkes, Jeffry S Nyman. Bone 2020
8


Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.
Sanjay Kalra, Kimi K Shetty, Vertivel B Nagarajan, Jignesh K Ved. Diabetes Ther 2020
6

Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice.
Kana N Miyata, Shuiling Zhao, Chin-Han Wu, Chao-Sheng Lo, Anindya Ghosh, Isabelle Chenier, Janos G Filep, Julie R Ingelfinger, Shao-Ling Zhang, John S D Chan. Diabetes Res Clin Pract 2020
4


Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
15

Non-insulin therapies in addition to insulin in Type 1 DM treatment.
Andrea Llano, Gerard A McKay. Br Med Bull 2020
1

Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes.
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
3

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
4

Pharmacological therapies to address obesity in type 1 diabetes.
Anna Casu, Anika Bilal, Richard E Pratley. Curr Opin Endocrinol Diabetes Obes 2020
1

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
2


SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu. Ther Adv Endocrinol Metab 2020
4

Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.
Raffaella Buzzetti, Tiinamaija Tuomi, Didac Mauricio, Massimo Pietropaolo, Zhiguang Zhou, Paolo Pozzilli, Richard David Leslie. Diabetes 2020
19

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
5

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes.
Pieter Gillard, Oliver Schnell, Per-Henrik Groop. Diabetes Res Clin Pract 2020
2

An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Georgios Chatzopoulos, Konstantinos Tziomalos. Expert Opin Pharmacother 2020
1